<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03179618</url>
  </required_header>
  <id_info>
    <org_study_id>XFZY-2017</org_study_id>
    <nct_id>NCT03179618</nct_id>
  </id_info>
  <brief_title>Research on the Clinical Effect of Xuefu Zhuyu Decoction in Treating Unstable Angina.</brief_title>
  <official_title>Research on the Clinical Effect of Xuefu Zhuyu Decoction in Treating Unstable Angina.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jun Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the clinical efficacy of Xuefu Zhuyu Decoction in the treatment of
      unstable angina pectoris. All of the patients will be divided into 2 arms randomly. One of
      the arms will be treated by conventional western medicine, the other one will be treated by
      Xuefu Zhuyu Decoction at the base of conventional western medicine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Xuefu Zhuyu Decoction has the function of activating qi and promoting blood circulation,
      which will be used to treat patients with qi stagnation and blood stasis syndrome.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>Six months after drug intervention</time_frame>
    <description>Death caused by cardiovascular disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myocardial enzymes</measure>
    <time_frame>At baseline and 4 weeks after drug intervention</time_frame>
    <description>The unit is mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3. Blood lipid The unit is mmol/L. Blood lipid</measure>
    <time_frame>At baseline and 4 weeks after drug intervention</time_frame>
    <description>3. Blood lipid The unit is mmol/L. 3. Blood lipid The unit is mmol/L. The unit is mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treadmill exercise test</measure>
    <time_frame>At baseline and 4 weeks after drug intervention</time_frame>
    <description>The result will be positive or negative</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of myocardial infarction or heart failure</measure>
    <time_frame>Six months after drug intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Unstable Angina</condition>
  <arm_group>
    <arm_group_label>Qi stagnation and blood stasis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will be treated by Xuefu Zhuyu Decoction at the base of conventional western medicine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional western medicine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients in this group will be treated by conventional western medicine, including anti-platelet drugssï¼Œlipid regulating drugs, coronary vasodilator, etc.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-Platelet Drugs</intervention_name>
    <description>Including aspirin and clopidogrel, etc.</description>
    <arm_group_label>Qi stagnation and blood stasis</arm_group_label>
    <arm_group_label>Conventional western medicine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lipid Regulating Drugs</intervention_name>
    <description>Mainly including statins</description>
    <arm_group_label>Qi stagnation and blood stasis</arm_group_label>
    <arm_group_label>Conventional western medicine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Coronary Vasodilator</intervention_name>
    <description>Mainly including nitrates</description>
    <arm_group_label>Qi stagnation and blood stasis</arm_group_label>
    <arm_group_label>Conventional western medicine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xuefu Zhuyu Decoction</intervention_name>
    <description>Mainly including Peach Kernel, Safflower, Angelica, Bupleurum etc.</description>
    <arm_group_label>Qi stagnation and blood stasis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants diagnosed with coronary heart disease through coronary angiography or
             coronary CTA;

        Patients have at least one of these symptoms:

          1. The stability of the nature of angina pectoris changes, that is, frequent attacks of
             angina pectoris, serious degree and prolonged duration;

          2. Angina pectoris during rest;

          3. The recent occurrence of angina pectoris caused by mild physical activity in the last
             month.

        Exclusion Criteria:

          -  Patients diagnosed with stable angina; Patients with acute myocardial infarction;
             Chest pain caused by congenital heart disease, valvular heart disease, severe neurosis
             or arrhythmia; The heart function grade is III or IV; Patients with acute cerebral
             infarction; Patients complicated with other serious primary diseases; Patients with
             acute infection in recent 2 weeks; Uncontrolled hypertension (the resting blood
             pressure &gt;160/95mmHg within one week); Diabetics emerged with serious diabetic
             complications; Patients can't finish the questionnaire due to abnormal mental and
             nervous or mental disorders; Pregnant or lactating women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Li, MD</last_name>
    <role>Study Director</role>
    <affiliation>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Panpan Tian</last_name>
    <phone>+86 15652388175</phone>
    <email>15652388175@163.com</email>
  </overall_contact>
  <results_reference>
    <citation>Yi GZ, Qiu YQ, Xiao Y, Yuan LX. The usefulness of xuefu zhuyu tang for patients with angina pectoris: a meta-analysis and systematic review. Evid Based Complement Alternat Med. 2014;2014:521602. doi: 10.1155/2014/521602. Epub 2014 Aug 31. Review.</citation>
    <PMID>25254054</PMID>
  </results_reference>
  <results_reference>
    <citation>Qiu Y, Xu H, Shi D. Traditional chinese herbal products for coronary heart disease: an overview of cochrane reviews. Evid Based Complement Alternat Med. 2012;2012:417387. doi: 10.1155/2012/417387. Epub 2012 Mar 28.</citation>
    <PMID>22536282</PMID>
  </results_reference>
  <results_reference>
    <citation>Liu W, Xiong X, Yang X, Chu F, Liu H. The Effect of Chinese Herbal Medicine Gualouxiebaibanxia Decoction for the Treatment of Angina Pectoris: A Systematic Review. Evid Based Complement Alternat Med. 2016;2016:8565907. Epub 2016 Sep 29. Review.</citation>
    <PMID>27777598</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang J, Yang X, Chu F, Chen J, He Q, Yao K, Teng F, Gao Y, Xing Y, Wu A, Xing Y. The effects of xuefu zhuyu and shengmai on the evolution of syndromes and inflammatory markers in patients with unstable angina pectoris after percutaneous coronary intervention: a randomised controlled clinical trial. Evid Based Complement Alternat Med. 2013;2013:896467. doi: 10.1155/2013/896467. Epub 2013 May 8.</citation>
    <PMID>23737852</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang J, Yu G. A Systems Biology Approach to Characterize Biomarkers for Blood Stasis Syndrome of Unstable Angina Patients by Integrating MicroRNA and Messenger RNA Expression Profiling. Evid Based Complement Alternat Med. 2013;2013:510208. doi: 10.1155/2013/510208. Epub 2013 May 14.</citation>
    <PMID>23762142</PMID>
  </results_reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2017</study_first_submitted>
  <study_first_submitted_qc>June 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2017</study_first_posted>
  <last_update_submitted>June 5, 2017</last_update_submitted>
  <last_update_submitted_qc>June 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</investigator_affiliation>
    <investigator_full_name>Jun Li</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <keyword>Unstable Angina</keyword>
  <keyword>Xuefu Zhuyu Decoction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Angina, Unstable</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasodilator Agents</mesh_term>
    <mesh_term>Platelet Aggregation Inhibitors</mesh_term>
    <mesh_term>Lipid Regulating Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

